(Q41477974)

1 October 2017

1 reference

title

Progressive visual loss from giant cell arteritis despite high-dose intravenous methylprednisolone (English)

1 reference

1 October 2017

1 reference

1

Cornblath WT

1 reference

1 October 2017

2

Eggenberger ER

1 reference

1 October 2017

publication date

1 May 1997

1 reference

1 October 2017

1 reference

1 October 2017

volume

104

1 reference

1 October 2017

issue

5

1 reference

1 October 2017

page(s)

854-858

1 reference

Temporal arteritis. A 14-year epidemiological, clinical and prognostic study

1 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930222-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930222-X

1 reference

7 January 2021

Temporal arteritis--progressive affection of vision during high-level corticosteroid therapy. A case report

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930222-X

7 January 2021

Giant cell arteritis (temporal arteritis) presenting as fever of undetermined origin

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930222-X

7 January 2021

Reversal of blindness in temporal arteritis with methylprednisolone

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930222-X

7 January 2021

Treatment of temporal arteritis with ocular involvement

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930222-X

7 January 2021

Treatable blindness in temporal arteritis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930222-X

7 January 2021

Visual Recovery in Two Patients after Intravenous Methylprednisolone Treatment of Central Retinal Artery Occlusion Secondary to Giant-cell Arteries

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930222-X

7 January 2021

Visual prognosis in giant cell arteritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930222-X

7 January 2021

Visual morbidity in giant cell arteritis. Clinical characteristics and prognosis for vision

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930222-X

7 January 2021

Progressive Anterior Ischemic Optic Neuropathy due to Giant Cell Arteritis Despite High-Dose Intravenous Corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930222-X

7 January 2021

Giant cell arteritis. Corticosteroids, temporal artery biopsy, and blindness.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930222-X

7 January 2021

Fatal Arrhythmia After Pulse Methylprednisolone Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930222-X

7 January 2021

Sudden death after methylprednisolone pulse therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930222-X

7 January 2021

Seizure after pulse therapy with methyl prednisolone

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930222-X

7 January 2021

Anaphylaxis following administration of intravenous methylprednisolone sodium succinate

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930222-X

7 January 2021

Sudden death after treatment with pulsed methylprednisolone

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930222-X

7 January 2021

Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930222-X

7 January 2021

A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930222-X

7 January 2021

10.1016/S0161-6420(97)30222-X

Identifiers

DOI

1 reference

1 October 2017

1 reference